The use of pramipexole in Parkinson's disease: are its actions D(3) mediated?
Identifieur interne : 000157 ( Ncbi/Merge ); précédent : 000156; suivant : 000158The use of pramipexole in Parkinson's disease: are its actions D(3) mediated?
Auteurs : M. Guttman [Canada] ; J. JaskolkaSource :
- Parkinsonism & related disorders [ 1873-5126 ] ; 2001.
Abstract
Pramipexole is a non-ergot dopamine agonist recently approved for the treatment of early and advanced Parkinson's disease (PD). It has preferential affinity for the D(3) dopamine receptor, compared to previous dopamine agonists that have higher affinity for D(2) dopamine receptors. The ultimate question is whether its efficacy is linked to its action at the D(3) dopamine site or due to its binding to D(2) dopamine receptors. There is no direct experimental evidence available to answer this question. Based on a review of the pharmacological literature, it is likely that the motor benefits of pramipexole in PD patients are due to D(2) stimulation, whereas its putative effects on mood and apathy may be related to its D(3) agonist properties.
PubMed: 11331191
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001567
- to stream PubMed, to step Curation: 001567
- to stream PubMed, to step Checkpoint: 001567
Links to Exploration step
pubmed:11331191Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of pramipexole in Parkinson's disease: are its actions D(3) mediated?</title><author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M" last="Guttman">M. Guttman</name><affiliation wicri:level="1"><nlm:affiliation>Division of Neurology, Department of Medicine and Department of Psychiatry, National Parkinson Foundation Centre of Excellence, University of Toronto and Centre for Addiction and Mental Health, Ont., Toronto, Canada</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Department of Medicine and Department of Psychiatry, National Parkinson Foundation Centre of Excellence, University of Toronto and Centre for Addiction and Mental Health, Ont., Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Jaskolka, J" sort="Jaskolka, J" uniqKey="Jaskolka J" first="J" last="Jaskolka">J. Jaskolka</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11331191</idno><idno type="pmid">11331191</idno><idno type="wicri:Area/PubMed/Corpus">001567</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001567</idno><idno type="wicri:Area/PubMed/Curation">001567</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001567</idno><idno type="wicri:Area/PubMed/Checkpoint">001567</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001567</idno><idno type="wicri:Area/Ncbi/Merge">000157</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The use of pramipexole in Parkinson's disease: are its actions D(3) mediated?</title><author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M" last="Guttman">M. Guttman</name><affiliation wicri:level="1"><nlm:affiliation>Division of Neurology, Department of Medicine and Department of Psychiatry, National Parkinson Foundation Centre of Excellence, University of Toronto and Centre for Addiction and Mental Health, Ont., Toronto, Canada</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Department of Medicine and Department of Psychiatry, National Parkinson Foundation Centre of Excellence, University of Toronto and Centre for Addiction and Mental Health, Ont., Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Jaskolka, J" sort="Jaskolka, J" uniqKey="Jaskolka J" first="J" last="Jaskolka">J. Jaskolka</name></author></analytic><series><title level="j">Parkinsonism & related disorders</title><idno type="eISSN">1873-5126</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pramipexole is a non-ergot dopamine agonist recently approved for the treatment of early and advanced Parkinson's disease (PD). It has preferential affinity for the D(3) dopamine receptor, compared to previous dopamine agonists that have higher affinity for D(2) dopamine receptors. The ultimate question is whether its efficacy is linked to its action at the D(3) dopamine site or due to its binding to D(2) dopamine receptors. There is no direct experimental evidence available to answer this question. Based on a review of the pharmacological literature, it is likely that the motor benefits of pramipexole in PD patients are due to D(2) stimulation, whereas its putative effects on mood and apathy may be related to its D(3) agonist properties.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">11331191</PMID><DateCreated><Year>2001</Year><Month>05</Month><Day>01</Day></DateCreated><DateRevised><Year>2001</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-5126</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Parkinsonism & related disorders</Title><ISOAbbreviation>Parkinsonism Relat. Disord.</ISOAbbreviation></Journal><ArticleTitle>The use of pramipexole in Parkinson's disease: are its actions D(3) mediated?</ArticleTitle><Pagination><MedlinePgn>231-234</MedlinePgn></Pagination><Abstract><AbstractText>Pramipexole is a non-ergot dopamine agonist recently approved for the treatment of early and advanced Parkinson's disease (PD). It has preferential affinity for the D(3) dopamine receptor, compared to previous dopamine agonists that have higher affinity for D(2) dopamine receptors. The ultimate question is whether its efficacy is linked to its action at the D(3) dopamine site or due to its binding to D(2) dopamine receptors. There is no direct experimental evidence available to answer this question. Based on a review of the pharmacological literature, it is likely that the motor benefits of pramipexole in PD patients are due to D(2) stimulation, whereas its putative effects on mood and apathy may be related to its D(3) agonist properties.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guttman</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine and Department of Psychiatry, National Parkinson Foundation Centre of Excellence, University of Toronto and Centre for Addiction and Mental Health, Ont., Toronto, Canada</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaskolka</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Parkinsonism Relat Disord</MedlineTA><NlmUniqueID>9513583</NlmUniqueID><ISSNLinking>1353-8020</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>5</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11331191</ArticleId><ArticleId IdType="pii">S1353-8020(00)00062-6</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Jaskolka, J" sort="Jaskolka, J" uniqKey="Jaskolka J" first="J" last="Jaskolka">J. Jaskolka</name></noCountry><country name="Canada"><noRegion><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M" last="Guttman">M. Guttman</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000157 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000157 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:11331191
|texte= The use of pramipexole in Parkinson's disease: are its actions D(3) mediated?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:11331191" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |